CytomX Therapeutics (CTMX) Current Leases (2019 - 2026)
CytomX Therapeutics' (CTMX) quarterly Current Leases came in at $2.9 million in Q1 2026, down 46.04% YoY from $5.3 million in Q1 2025, and down 32.64% on a QoQ basis from $4.2 million in Q4 2025.
CytomX Therapeutics (CTMX) Current Leases (2019 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 8 years of Current Leases data on file, last reported at $2.9 million in Q1 2026.
- Quarterly Current Leases fell 46.04% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 46.04% YoY) and the FY2025 annual result came in at $4.2 million, down 17.59% from the prior year.
- Current Leases retreated to $2.9 million in Q1 2026, from $4.2 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $5.6 million in Q3 2025 to a low of $2.9 million in Q1 2026.
- A 5-year average of $4.5 million and a median of $4.5 million in 2023 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases climbed 12.82% — and 2026, when it tumbled 46.04%.
- Tracing CTMX's Current Leases over 5 years: stood at $4.1 million in 2022, then advanced by 12.42% to $4.6 million in 2023, then grew by 12.12% to $5.1 million in 2024, then slipped by 17.59% to $4.2 million in 2025, then sank by 32.64% to $2.9 million in 2026.
- The last three Current Leases figures came in at $2.9 million (Q1 2026), $4.2 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Mar 31, 2026 | 2.86 Mn |
| Dec 31, 2025 | 4.24 Mn |
| Sep 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 5.44 Mn |
| Mar 31, 2025 | 5.29 Mn |
| Dec 31, 2024 | 5.15 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 4.86 Mn |
| Mar 31, 2024 | 4.72 Mn |
| Dec 31, 2023 | 4.59 Mn |
| Sep 30, 2023 | 4.46 Mn |
| Jun 30, 2023 | 4.33 Mn |
| Mar 31, 2023 | 4.20 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Sep 30, 2022 | 3.96 Mn |
| Jun 30, 2022 | 3.85 Mn |
| Mar 31, 2022 | 3.73 Mn |
| Dec 31, 2021 | 3.62 Mn |
| Jun 30, 2020 | 3.00 Mn |